Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BX-U001
- Development stage
- Phase 2
- Lead developer
- Baylx
- Modality
- Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
BX-U001 is an allogeneic human umbilical cord tissue-derived mesenchymal stem cell (hUC-MSC) product developed by Baylx for the treatment of inflammatory and autoimmune diseases. The product consists of fresh, non-frozen hUC-MSCs administered intravenously. Its primary mechanism is immunomodulation through cell replacement and anti-inflammatory effects. Preclinical studies have demonstrated that BX-U001 can significantly reduce pro-inflammatory cytokines such as IL-6 and alleviate symptoms in models of rheumatoid arthritis (RA). The cells are harvested shortly before administration to maintain optimal viability without cryoprotectants. Clinical development has focused on RA and COVID-19-associated acute respiratory distress syndrome (ARDS), with additional exploration in other inflammatory conditions[1][2][3][5][6][7].
- Other names
- hUC-MSC suspension - BaylxHuman umbilical cord tissue-derived mesenchymal stem cell therapy - Baylx
Beyond the preview
Go deeper on BX-U001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BX-U001.